Clinical Trials

BREASTCDX-011-04 –  Triple Negative Metastatic Breast Cancer, 1st or 2nd Line
A Randomized Multicenter Pivotal Study of CDX-011 (CR011-vcMMAE)in Patients With Metastatic, gpNMB Over-Expressing, Triple Negative Breast Cancer (The METRIC Study)
Learn More

BREAST: CP-MGAH22-04 (SOPHIA) – HER2 Positive, Metastatic A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients With HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment
Learn More

GEJ or STOMACH: GS-US-296-1080 – 1st Line, Locally Advanced or Metastatic
A Phase 3 Randomized, Double-Blind, Placebo-ControlledStudy to Evaluate the Efficacy and Safety of GS-5745Combined with mFOLFOX6 as First Line Treatment in Patients with Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Learn More

LUNG:   BioDyn-15-003 –  TR(ACE) Assay Clinical Specimen Study
Evaluation of the TR(ACE)® Assay for the Ability to Aid in Monitoring Disease Progress, Response to Therapy or for the Recurrent or Residual Disease for Patients with Previously Diagnosed Cancers (Stage III and IV Lung)
Learn More

LUNG:   INI-001 –  Blood Biopsy vs. Tissue  –  Prospective observational multicenter study to evaluate the performance of Inivata liquid biopsy analysis compared with standard tissue biopsy analysis for detection of genomic alterations in patients with advanced non-small cell lung cancer.
Learn More

PANCREATIC: EP-GF-301 – 2ND Line, Metastatic
A Randomized Phase 3 Study of the Efficacy and Safety of Glufosfamide Compared with Flourouracil (5-FU) in Patients with Metastatic Pancreatic Adenocarcinoma Previously Treated with Gemcitabine
Learn More

SOLID TUMOR:  EMR200647-001  – Metastatic or Locally Advanced
A Phase I, open-label, multiple-ascending dose trial to investigate the safety, tolerability, pharmacokinetics, biological and clinical activity of MSB0011359C in subjects with metastatic or locally advanced solid tumors and expansion to selected indications
Learn More

************************************************************************************************************************************************************************************

PULMONARY:   RIN-PH-201 (INCREASE) – Pulmonary Hypertension PLD
A Multicenter, Randomized, Double-Blinded, Placebo-Controlled Trial to Evaluate the Safety and Efficacy of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Learn More

PULMONARY:   RIN-PH-202 (INCREASE-OL) – Pulmonary Hypertension PLD
An Open-Label Extension study of Inhaled Treprostinil in Subjects with Pulmonary Hypertension due to Parenchymal Lung Disease
Learn More

************************************************************************************************************************************************************************************

RADIATION THERAPY: NRG BN-001 –  Brain
Randomized Phase II Trial Of Hypofractionated Dose-Escalated Photon IMRT OR Proton Beam Therapy Versus Conventional Photon Irradiation With Concomitant And Adjuvant Temozolomide In Patients With Newly Diagnosed Glioblastoma
Learn More

RADIATION THERAPY:   PRO 1401– Prostate
A Phase II Study of Hypofractionated Image Guided Proton Therapy for Low and Intermediate Risk Prostate Cancer
Learn More

RADIATION THERAPY:   PARTIQoL 11-497    Prostate
PARTIQoL: Prostate Advanced Radiation Technologies Investigating Quality of Life: A Phase III Randomized Clinical Trial of Proton Therapy vs. IMRT for Low or Intermediate Risk Prostate Cancer
Learn More

RADIATION THERAPY:   PRO 0425 – Proton Cancer Registry
Registry Study for Proton Therapy Clinical Outcomes and Long-Term Follow-up
Learn More

RADIATION THERAPY: RADCOMP –  Breast
Pragmatic Phase Iii Randomized Trial Of Proton Vs. Photon Therapy For Patients With Non-Metastatic Breast Cancer Receiving Comprehensive Nodal Radiation: A Radiotherapy Comparative Effectiveness (Radcomp) Consortium Trial
Learn More

RADIATION THERAPY: RTOG 1308 –  Non-Small Cell Lung
Phase III Randomized Trial Comparing Overall Survival After Photon Versus Proton Chemoradiotherapy for Inoperable Stage II-IIIB NSCLC
Learn More

************************************************************************************************************************************************************************************

URINARY:   B9991003 – Renal Cell
A Phase 3, Multinational, Randomized, Open-Label, Parallel-Arm Study Of Avelumab (Msb0010718c) In Combination With Axitinib (Inlyta ®) Versus Sunitinib (Sutent ®) Monotherapy In The First-Line Treatment Of Patients With Advanced Renal Cell Carcinoma
Learn More

URINARY:   178-MA-1008 – Bladder
A Phase 4, Double-Blind, Randomized, Placebo-controlled, Multi-Center Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men with Overactive Bladder (OAB) Symptoms While Taking the Alpha Blocker Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH)
Learn More

URINARY:   VB4-845-02-IIIA – Bladder
Open-Label, Multicenter, Ph 3 Study to Evaluate the Efficacy and Tolerability of Intravesical Vicinium™ in Subjects With Non Muscle-Invasive Carcinoma in Situ and/or High-Grade Papillary Disease of the Bladder Treated With BCG
Learn More

 

Corporate Office

1400 Dowell Springs Blvd.,
Suite 350, Knoxville, TN 37909
Phone: (865) 934-2670
Send us an Email
Privacy Practices

Research Office

1415 Old Weisgarber Road,
Suite 200, Knoxville, TN 37909
Phone: (865) 934-2670
Send us an Email